



KRKA, D.D.

Sector: Pharmaceuticals
 Bloomberg ticker: KRKG SV


COMPANY INTRODUCTION

SHARES:	
TICKER:	KRKG
NUMBER OF SHARES:	
Common:	3,542,612
Preferred:	0
All:	3,542,612
PRICE EUR (20.03.2007):	810.87
BV (31.12.2006):	158.81
MARKET CAP. mn EUR:	2,872.60

RATIOS:	
P/E:	25.81
P/B:	5.11
P/S:	4.30
DY:	0.85%
EPS:	32.93
ROE:	19.78%
ROA:	12.67%

	Date	Price	Ch %
Last	20.03.07	810.87	0.0
Min:	30.12.05	427.18	-47.3
Max:	02.02.07	917.13	13.1
2006	27.12.06	784.75	-3.2

Krka is one of the leading generic pharmaceutical companies which operate in Slovenia, Central and Eastern Europe. It is also expanding its positions to Western markets. Besides prescribed medicines and self-treatment medicine, the company also produces veterinary and cosmetic products and implements health and tourist service via its affiliate company Krka Zdravilišča (Krka Health Resorts).



Around 29% of its products are sold in the area of Eastern Europe, 25% in Central Europe, 16% in the area of South Eastern Europe and 15% in the area of Western Europe and overseas. Approximately 15% of its products are sold on Slovenian market.

The production aims at producing products for self-treatment by emphasizing specific needs of a rapidly aging population. The offer is expanded in the fields of modern diseases: cardiovascular system, infections, digestion and nervous system.

In 2006 the net revenues of Krka group amounted to EUR 667.9 mn increasing 21% from the year before. The operating profit increased 26% to EUR 150.5 mn and the net profit in the amount of EUR 111.3 mn was 15% higher than in 2005. Net sales revenues of the parent company amounted to EUR 586.1 mn, an increase of 20%. The operating profit reached EUR 147 mn, which is 22% higher and the net profit amounted to EUR 113 mn, which is 21% higher than in 2005.

Krka is planning to maintain its market share and one of its most important goals is to expand to European and central Asian markets. Besides producing generic drugs, the company develops its own products and will in the future consolidate relations with its licence partners. Krka anticipates a 15 % increase in profit in the future years.

OWNERSHIP STRUCTURE

Shareholder	No. of shares	% stake	Cumulative % stake
SLOVENSKA ODŠKODNINSKA DRUŽBA, D.D.	531,207.00	14.99	14.99
KAPITALSKA DRUŽBA, D.D.	349,303.00	9.86	24.85
KRKA, D.D., NOVO MESTO	162,662.00	4.59	29.45
NFD 1 DELNIŠKI INVESTICIJSKI SKLAD D.D.	94,267.00	2.66	32.11
NEW WORLD FUND INC	64,051.00	1.81	33.92
BANK AUSTRIA CREDITANSTALT AG	47,857.00	1.35	35.27
DELNIŠKI VZAJEMNI SKLAD TRIGLAV STEBER I	44,847.00	1.27	36.53
LUKA KOPER, D.D.	42,103.00	1.19	37.72
ZAVAROVALNICA TRIGLAV, D.D.	38,830.00	1.10	38.82
MARIBORSKE LEKARNE MARIBOR	30,000.00	0.85	39.66

KEY FINANCIAL DATA

000 EUR	Group			Company		
	2006	2005	06/05	2006	2005	06/05
INCOME STATEMENT						
Net sales revenues	667,955	554,137	21%	586,102	486,439	20%
Operating profit	150,495	119,057	26%	146,965	120,184	22%
EBITDA	198,200	164,849	20%	183,159	155,148	18%
Profit before tax	148,756	123,226	21%	147,250	118,300	24%
Net profit	111,287	97,182	15%	113,027	93,721	21%
BALANCE SHEET						
Total assets	878,691	788,054	12%	854,286	759,220	13%
Total equity	562,604	471,889	19%	569,918	476,300	20%
Minority interest	7,864	7,568	4%	-	-	-

CONTACT

Matjaž Bernik
Head of Trading Department
Ilirika Brokerage House PLC, Trdinova 3, 1000 Ljubljana, Slovenia
Tel: +386 1 300 22 55
Fax: +386 1 234 33 59
e-mail: matjaz.bernik@ilirika.si

DISCLAIMER

Ilirika borzno posredniška hiša Plc. is an authorized member of the Ljubljana Stock Exchange and is controlled by the Securities Market Agency of the Republic of Slovenia. This report has no regard to the individual investment objectives, financial situation or particular needs of any specific recipient and should not be relied upon as authoritative, or taken in substitution for the exercise of judgment by any receiver. Each recipient should consider the appropriateness of any investment decision having regard to their own circumstances, the full range of information available and appropriate professional advice, and should consult their advisors to make sure all involved risks are fully understood. The information and opinions in this report constitute judgment as at the date of this report, have been compiled or arrived at from sources believed to be reliable, but no representation or warranty, express or implied, is made as to their accuracy, completeness or correctness. Opinions expressed herein are subject to change without notice. This report is not intended to be a complete statement or summary of the securities, markets or developments mentioned in this report. Any forecasts or price targets shown for companies discussed in this report may not be achieved due to multiple risk factors including, without limitation, market volatility, sector volatility, corporate actions, the unavailability of complete and accurate information and/or the subsequent transpiration that underlying assumptions made by Ilirika, or by other sources relied upon in the report, were inapposite. Ilirika accepts no liability whatsoever for any loss or damage arising from any use of this report or its contents. The recipient should presume that Ilirika, or persons or entities associated with it, or any of its clients, own or have a position in any securities or investments mentioned in this study, which position may change at any time. Ilirika or its Affiliates may buy, sell or offer to buy or sell, such securities or any related investments as principal or agent on the open market or trade as market makers in the securities mentioned herein. Ilirika is under no obligation to update or keep current the information contain herein.